Promising results have been shown in an animal model of Alzheimer's disease treated with zinc finger protein transcription factors.
List view / Grid view
Alzheimer's disease (AD)
Scientists have developed a model of the early stages of Alzheimer's disease in rhesus macaques to better test new treatments.
Researchers have developed a new tool that can add or remove sugar from proteins, which could be used to treat currently "undruggable" targets.
Researchers have used artificial intelligence to screen 80 FDA-approved drugs and reveal which could be used as Alzheimer's treatments.
Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
The discovery of early plasma biomarkers for Alzheimer's disease could transform outcomes by enabling patients to begin treatment early.
The discovery of an inflammatory pathway promoting brain ageing and cognitive decline could lead to new treatments for age-related conditions.
Tests in Alzheimer's disease mouse models have shown that hydrogen sulphide can improve cognitive and motor function by 50 percent.
According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.